Interactive Session:
128. Susceptibility Breakpoints: Controversies, Challenges, and Changes
Friday, October 4, 2013: 2:00 PM-3:30 PM
Room: The Moscone Center: Esplanade Ballroom 301-310

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the various organizations and agencies that establish susceptibility breakpoints
  • discuss the controversies and challenges associated with the process of establishing or revising susceptibility breakpoints
  • outline the use of susceptibility breakpoints to guide the choice and dosing regimen for antimicrobial agents

Target Audience: scientists, researchers, pharmacists, nurses, microbiologists, members-in-training, lab personnel, investigators, infectious diseases physicians, infectious diseases pediatricians, hospital epidemiologists, fellows, epidemiologists, clinicians, academicians

Tracks: Investigative ID, Global ID, Epidemiology and Infection Control, Adult ID

Moderators:  David Andes, MD, University of Wisconsin and Paul G. Ambrose, PharmD, FIDSA, Institute of Clinical Pharmacodynamics


2:20 PM
EUCAST: Setting International Breakpoints
Gunnar Kahlmeter, MD, PhD

2:40 PM

CME Credits: ***CME Credit Approved*** Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-110-L01-P


D. Andes, None

P. G. Ambrose, None

F. Marsik, The Medicines Company: Consultant, Consulting fee
Pfizer: Shareholder, Purchased my own shares - Nothing received from Pfizer
Cubist Pharmaceuticals, Inc.: Consultant, Consulting fee

G. Kahlmeter, None

R. Jones, None

M. Wikler, CLSI: Board Member, NONE, Volunteer Position

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.